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Highlights 
 A further shrimp chondroitin sulfate (sCS) was structurally characterized; 
 sCS presents the rare 3-O-Sulfo-glucuronic acid residue; 
 sCS inhibits thrombin and modulates in vivo inflammation  
 
 
Abstract 
The detailed structure of a further Chondroitin Sulfate from Litopenaeus 
vannamei shrimp (sCS) is described. The backbone structure was established by 1H/13C  
NMR, which identified 3-O-sulfated GlcA, 4-O-sulfated GalNAc, 6-O-sulfated 
GalNAc, and 4,6-di-O-sulfated GalNAc residues. GlcA is linked to GalNAc 4,6 di S 
and GlcA 3S is linked to GalNAc 4S, GalNAc 4,6 di-S and GalNAc6S residues. The 
anticoagulant properties of this sCS were evaluated by activated partial thromboplastin 
time, anti-IIa, anti-Xa and anti-heparin cofactor II-mediated activities, and sCS failed to 
stabilise antithrombin in a fluoresence shift assay. The anti-inflammatory effect of sCS 
was explored using a model of acute peritonitis, followed by leukocyte count and 
measurement of the cytokines, IL-1β, IL-6 and TNF-α. The compound showed low 
clotting effects, but high anti-IIa activity and HCII-mediated thrombin inhibition. Its 
anti-inflammatory effect was shown by leukocyte recruitment inhibition and a decrease 
in pro-inflammatory cytokine levels. Although the biological role of sCS remains 
unknown, its properties indicate that it is suitable for studies of multi-potent molecules 
obtained from natural sources. 
 
Key-words: Chondroitin sulfate, inflammation, shrimp, thrombin. 
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Introduction 
Chondroitin sulfate (CS) is a sulfated linear polysaccharide of the 
glycosaminoglycan (GAG) family, composed of β(1-4) linked disaccharide units, 
themselves comprising β-D-glucuronic acid (GlcA) (1→3) linked to N-acetyl-D-
galactosamine (GalNAc) (Prabhakar & Sasisekharan, 2006; Tomatsu et al., 2015). 
Several types of CS structures have been reported and have been classified according to 
their GlcA and GalNAc sulfation patterns. Under this system of nomenclature, GalNAc 
residues sulfated at the C-4 and/or C-6 positions give rise to CS-A [GlcA-GalNAc 4-O-
sulfate], CS-C [GlcA-GalNAc 6-O-sulfate] and CS-E [GlcA–GalNAc 4,6-di-O-sulfate] 
units respectively. GlcA residues exhibit O-sulfation at C-2 and more rarely at C-3, 
giving rise to CS-D [GlcA 2-O-sulfate-GalNAc 6-O-sulfate], CS-K [GlcA 3-O-sulfate-
GalNAc 4-O-sulfate] and CS-S [GlcA 2,3 di-O-sulfate-GalNAc 4 or 6-O-sulfate] units, 
respectively (Cavalcante et. al., 2018; Nandini & Sugahara, 2006; Pavão, Vilela-Silva & 
Mourão 2006; Volpi 2006). Furthermore, sulfated fucose branches in GlcA residues are 
common in natural CS (Kale et al., 2013; Mou et al., 2018). It should be stressed, 
however, that CS polysaccharides isolated from invertebrates are rarely so well-defined; 
different sections of the CS chains often correspond to several of these supposed 
prototypical CS types. Recently, CS polysaccharides have attracted attention due to 
their participation in various biological events. Thus, the search for naturally occurring, 
novel CS (Deepa et. al. 2007; Shetty et.al. 2009; Toida et. al. 2015) has expanded, along 
with investigations into the relationship between their structural features and biological 
functions. 
Sulfated GAGs are covalently bound to proteins to form several proteoglycans 
(PGs) that participate in numerous physiological phenomena. (Iozzo & Schaefer 2015; 
Ustyuzhanina et. al., 2018; Volpi, 2011).  The variety in the position and degree of 
sulfation, size, number and disaccharide sequences that are inserted in the CSPGs, make 
CS a heterogeneous molecules. The many biological effects of CS so far reported 
include inflammation, cell proliferation, differentiation, migration, tissue 
morphogenesis and wound repair (Krichen et. al., 2018; Mou et. al. 2018; Sugahara et 
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al., 2003). Crucially, differences in the structure of CS chains lead to distinct biological 
and pharmacological properties.  
Of all natural sources, marine GAGs stand out because of their structural 
peculiarities (Pomin & Morão, 2014). Recently, we characterized a CS from 
Litopenaeus vannamei shrimp (sCS) containing unusual 2,3-di-O-sulfated GlcA 
residues, which presented promising anticoagulant and antithrombotic activities 
(Cavalcante et. al., 2018). In addition, fucosylated CS structures obtained from distinct 
species of sea cucumber have been reported (Mou et. al., 2018; Ustyuzhanina et al., 
2016). One major difference between these resides in the sulfation patterns of the fucose 
branches, which significantly affect their in vitro antioxidant properties. Even though 
CS structures have been isolated from many vertebrate and invertebrate animal species, 
(Krishen et; al., 2018; Shetty et. al., 2009; Sugahara et.al., 1996; Volpi & Maccari, 
2007; Zhu et. al., 2018) the structural characterization of CS from invertebrate 
specimens reveals a rather narrow range of structures compared to those of marine 
species.   
Here, a further sCS from Litopenaeus vannamei shrimp, isolated under different 
conditions and structurally distinct from that reported earlier (Cavalcante et al., 2018), 
which possesses inhibitory effects on inflammation and potent anti-thrombin activity, is 
structurally characterized.   
 
Materials and methods 
 
1. Cell culture and reagents 
 
Murine macrophage cells (RAW 264.7) were grown in Dulbecco´s modified 
Eagle medium with 4.5 g.L-1 glucose supplemented with 10% fetal bovine serum and 20 
mM sodium bicarbonate (Cultilab, Campinas, SP, Brazil). All cultures were performed 
in culture plates (Falcon BD, San Jose, CA, USA). Unfractionated Sodium heparin from 
porcine mucosa was obtained from Laboratory Derivati Organici (Trino Vercellese, 
Italy). Other reagents were purchased from Sigma (St Louis, MO, USA).  
 
2. Animals 
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14 week old male Wistar rats weighing between 300 and 400 g and 12 week old 
female C57BL/6 mice (Departament of Biochemistry – Federal University of Rio 
Grande do Norte, Natal, Brazil) were used for in vivo experiments. Animals were 
housed in cages with free access to food and water and treated according to the ethical 
principles for animal experimentation. This study was carried out in strict accordance 
with the National Council on Animal Experimentation Control and specifically 
approved by the University of Rio Grande do Norte Ethics Committee. 
 
3. Extraction of glycosaminoglycans and purification of a sCS from L. 
vannamei  
 
  The extraction procedure for shrimp GAGs was performed as previously 
described (Brito et. al., 2008; 2014). Heads of Litopenaeus vannamei shrimp were 
obtained from shrimps cultivated in vivarium, kindly provided by ENSEG Indústria 
Alimentícia LTDA, Macaíba, Brazil.  Briefly, the shrimp heads were submitted to 
proteolysis and acetone treatment. The pool of GAGs obtained was fractionated using 
increasing volumes of acetone to obtain F-0.5A, F-0.7A and F-1.0A fractions. The sCS 
was then purified from F-1.0A, by further ion-exchange chromatography on DEAE-
Sephacel, followed by NaCl elution (see Supplementary Data Fig. S1A and agarose 
electrophoresis profile in Fig.S1B). The sCS compound evaluated in this present study 
was eluted with 1.0M NaCl and is a distinct population of sCS isolated from fraction F-
0,7A, previously reported (Cavalcante et al., 2018). Finally, the compounds were 
desalted by gel filtration through a Sephadex G-25 column by eluting with 10% ethanol. 
After lyophilization, this sCS sample was submitted to further analyses. 
 
4. Molecular weight determination 
The molecular weight (MW) of sCS was determined by gel permeation 
chromatography on a high-pressure liquid chromatography (GPC-HPLC) system, using 
a 300 × 7.8 mm BioSep SECTM S-2000 LC column (Phenomenex, Torrance, CA, USA). 
Twenty μL aliquots of sCS solution (10 mg/mL in 0.3 M Na2SO4 mobile phase) were 
applied into the GPC-HPLC system at a flow rate of 1 mL/min. UV detection was 
performed at 205 nm at room temperature. The column was previously calibrated with 
polysaccharides of known molecular weights; 1.7, 4.0, 10.0 and 16.0 kDa, 
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corresponding to fondaparinux sodium, enoxaparin, heparan sulfate and unfractionated 
heparin, respectively. 
 
5. Structural characterization 
Enzymatic digestion was performed as previously described by Lima et. al., 
2013. Briefly, 100 µg of the isolated compound were incubated overnight with 
chondroitinases ACII and ABC together (2.5 mIU each – TRIS-HCl PH 8.0, 60 mM 
sodium acetate). The disaccharides produced by exhaustive action of chondroitin ACII 
and ABC lyases on the chondroitin sulfate from L. vannamei and a mixture of 
disaccharide standards were resolved on a high performance liquid chromatography 
(HPLC) with 150 × 4.6 mm Phenosphere SAX column (Phenomenex, Torrance, CA, 
USA). The column was eluted with a NaCl gradient of 0–1 M during 30 min with a 1 
mL/min flux and UV detection at 232 nm. The peaks corresponded to the elution 
positions of known disaccharide standards as follows:  ΔUA β (1→3) GalNAc 6-O-
sulfate; ΔUA β (1→3) GalNAc 4-O-sulfate; ΔUA β(1→3) GalNAc 4,6-di-O-sulfate. 
However, resistance to chondroitinase digestion has been reported (Sugahara et. al., 
1996) and further investigations employing NMR spectroscopy were also undertaken. 
NMR experiments were performed on sCS in 200 µL of D2O containing 100 µM 
DSS at 343 K using a 600 MHz Bruker Avance II+ spectrometer fitted with a TCI 
CryoProbe. In addition to 1-dimensional (1H and 13C) spectra, both homonuclear 
(COSY, TOCSY and NOESY) and heteronuclear (HSQC and HMBC) 2-dimensional 
spectra were collected. TOCSY spectra were measured with a 120 ms mixing time 
while the mixing times for NOESY spectra were between 30 and 240 ms. Spectra were 
processed using Bruker TopSpin and assigned using the Collaborative Computing 
Project for NMR Analysis software (Vranken et al., 2005). 1H/13C HSQC integration 
was performed using the INFOS spectrum fitting software (Smith, 2017). Proton 
spectrum integration was performed using Bruker TopSpin software to calculate the 
proportion of each residue variant present within the polysaccharide sample. Full 
acquisition parameters are provided in Supplementary Data, Table ST1. 
 
6. Anticoagulant Activity assays  
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 Activated partial thromboplastin time (aPTT) assays were carried out according 
to the aPTTest manufacturer’s instructions (Labtest, Lagoa Santa, MG, Brazil). 
Unfractionated Heparin and sCS were diluted in saline and incubated with 90 µL of 
plasma and 100 μL of cephalin at 37 °C for 3 minutes. CaCl2 was added and the 
coagulation time was measured. The anti-IIa and anti-Xa activities were performed in 
96-well microplate according to the kit instructions Actichrome heparin (anti-fIIa) 
(American diagnostica Inc. Greenwich, CT, USA) and Biophen heparin anti-Xa kit 
(HYPHEN Biomed, ref: 221010), respectively. Antithrombin and thrombin were 
incubated with mammalian heparin or purified sCS at various concentrations at 37 °C 
for 2 min. After incubation, purified bovine factors Xa or IIa were added, mixed and 
incubated at 37 °C for 2 min. Next, the chromogenic substrate for factors Xa or IIa were 
added and the mixture incubated again for 2 min at 37 °C. Then, to stop the reaction, 
30% acetic acid was added and absorbance measured at 405 nm against a corresponding 
blank using a microplate reader (BioTek Epoch, Winooski, USA). A thrombin 
inhibition HCII-mediated assay was performed with the following reagents: 70 nM 
heparin cofactor II, 15 nM thrombin and 0-100 µl of the test sample and heparin in 25 
µl of 0.02 M Tris/HCl, 0.15 M NaCl (pH 7.4). Then, 25 µL of thrombin were added and 
incubated for 1 minute at 37 ºC. Thereafter, 25 uL of the chromogenic substrate N-
benzoyl-Phe-Val-Arg-p-nitroamilidahydrochloride (100 mM) were added and the 
mixture was incubated for 1 minute at 37 °C. 25 µL of 30% acetic acid were added to 
stop the reaction and the absorbance was read at 405 nm.   
 
7. Bleeding effect 
 
The residual hemorrhagic effect of the sample was analyzed by a modified model of 
topical scarification in rat tail (Cruz & Dietrich, 1967). A scarification was made 
(surgical blade) in the distal portion of the rat tail. Next, the scarified tail was dipped 
vertically in physiological saline solution, and dipped again in fresh saline to observe 
bleeding. Then, the tail was dipped in a solution containing the sCS or heparin at 
different concentrations over 2 mins and washed extensively with saline solution. The 
treated tail was immersed in new saline solutions over 40 mins, and the amount of 
protein from the lesion was determined by Bradford assay (Bradford, 1976). The results 
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were expressed as the sum of the protein values of each tube minus the amount of 
protein present before the exposure to the test substance. 
 
 
8. LPS-induced peritonitis 
 
C57BL/6 mice were injected with 100 µL of lipopolysaccharide (LPS, 055:B5 
strain, 3.3 mg Kg-1) or Phosphate-buffered saline (PBS), referred as ‘PBS control 
group’, into the peritoneal cavity. After 15 minutes, animals induced with LPS were 
injected intravenously with mammalian heparin, sCS (300 µg Kg-1 in PBS) or PBS 
alone (treatment control), referred as ‘PBS group’. 4 hours later, the peritoneal cavity 
was washed with 2 mL of PBS containing 0.5 % bovine serum albumin and 1 mM 
ethylenediaminetetraacetic acid (EDTA) in PBS. The total number of cells in the 
peritoneal lavage fluid was measured by hemocytometer. The differential count of 
polymorphonuclear leukocytes (PMN) was determined by cytospin preparations fixed 
with hematoxylin and eosin. 
 
9. Cytokine quantification  
 
 The peritoneal liquid of each treated group was collected after 4 hours of 
induction of inflammation with LPS and stored at -80 °C. The IL-1β, IL-6 and TNF-α 
levels were measured using enzyme immunoassay kit (ELISA) (eBioscience, San 
Diego, CA, USA) according to the manufacturer’s instructions. Each sample was 
measured in triplicate and the optical density of each well (assay performed in 96 well 
plates) was determined at 450 nm. 
 
10. Cell viability assay  
 
 RAW 264.7 cell viability was determined by the MTT (3- (4,5-
Dimethylthiazol-2-yl) -2,5-bromo diphenyltetrazolium) method (Mosmann, 1983). Cells 
were plated in 24 well plates (4.8 x 105 cells per well) and treated with different 
concentrations of GAGs. After 24 hours 350 µL per well of MTT solution (5 mg/mL) 
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were added. After 4 hour of incubation, cell supernatant was removed and 500 µL of 
dimethylsufoxide (DMSO) were added to all wells to lyse the cells and solubilize the 
crystals. The absorbance was determined at 570 nm. 
 
11. Nitric Oxide production quantification 
 
 RAW 264.7 cells (4.8 x 105 cells.100μL-1) were plated and induced with LPS 
(O55:B5 strain) and 1 hour later, treated with sCS or heparin (0.1, 1.0, 10 and 100 
μg/mL). After 24 hours, the supernatant was aspirated and submitted to nitric oxide 
(NO) dosage. In order to determine the total NO concentration, 50 µL of Griess reagent 
(1% sulfanilamide in 5% phosphoric acid and 0.1% naphthylethylenediamine 
dihydrochloride in water) were added to 50 μL of cell supernatant from each well. After 
30 minutes of incubation at room temperature, the absorbance was determined at 545 
nm with a microplate reader. 
 
12. Statistical analysis 
 
 Results were analyzed by two-way ANOVA and Bonferroni post-test and 
post-hoc Tukey test. Values of p < 0.01 and < 0.001 were considered indicative of 
statistical significance. 
 
Results and discussion 
 
1. Structural characterization 
The sCS from the shrimp cephalothorax isolated and fractionated as described above 
was purified using ion-exchange column, eluting with a NaCl stepwise (0.5 M; 0.8 M 
and 1.0 M) gradient. The sub-fraction eluting at 1.0 M NaCl, provided the sCS sample 
of the present study, which was then subjected to structural characterization. The 
molecular weight (Mw) was determined by GPC-HPLC as 12 kDa, corresponding to just 
under half of the average molecular weight (26 kDa) for another sCS isolated from L. 
vannamei shrimp under distinct conditions (Cavalcante et. al., 2018) and for bovine 
tracheal CS (Tomatsu, 2015). The present polysaccharide also differs from other CS 
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polysaccharides in terms of its composition and chain length (Sugahara et. al., 2003).  
Following treatment with chondroitinases ACII and ABC, products comprised 25.9 % 
of ΔU-GalNAc non-sulfated and 74.1 % of disaccharides bearing a sulfate ester at 4 or 6 
positions and both 4,6 (ΔU-GalNAc-4-O-sulfate; ΔU-GalNAc-6-O-sulfate and ΔU-
GalNAc-4,6 di-O-sulfate, respectively) (Fig.S2).  
Although the presence of significant proportions of the disaccharide ΔU-GalNAc-
4,6 di-O-sulfate by chondroitinase digestion and HPLC initially suggested a so-called 
CS-E type structure, following NMR, other structures were evident and these were 
investigated further. 
Structural characterization was performed using a combination of 1-dimensional (1H 
and 13C), homonuclear 2-dimensional (COSY, TOCSY and NOESY) and heteronuclear 
2-dimensional (HSQC and HMBC) NMR spectroscopy. The assignments for the 
hydrogen and carbon resonances and the chemical shift map of 1H/13C atoms (2-
dimensional 1H/13C HSQC) are shown in Fig. 1.  NMR characterization generated 1H 
and 13C assignments for eight constituent monosaccharide variants termed here; GlcA, 
GlcA-3Si, GlcA-3Sii, GalNAc4Si, GalNAc-4Sii, GalNAc-6Si, Gal-NAc-6Sii and 
GalNAc-4,6S present in the 2-dimensional 1H/13C HSQC spectrum (Fig. 1), where ‘S’ 
represents–O-sulfate and the superscripts i and ii denote signals from the same residue 
type, but in slightly different environments (most likely distinct adjacent residues). 
GlcA β(1→3) GalNAc linkages evident in both 1H/1H NOESY and 1H/13C HMBC 
spectra reveal four disulfated and one trisulfated disaccharide variants (continuing the 
nomenclature used above); GlcA β(1→3) GalNAc-4,6S, GlcA-3Si β(1→3) GalNAc-
4Si, GlcA-3Si β(1→3) GalNAc-4Sii, GlcA-3Si β(1→3) GalNAc-4,6S and GlcA-3Sii 
β(1→3) GalNAc-6Si. Inter-disaccharide linkages, GalNAc β(1→4) GlcA, were also 
observable in the 1H/1H NOESY and 1H/13C HMBC spectra between GalNAc-4Si and 
GlcA, GalNAc-4Sii and GlcA-3Si, GalNAc-4,6S and GlcA-3Sii, GalNAc-6Si and GlcA 
and GalNAc-6Sii and GlcA. The unusual GlcA-3S residue was identified through 
characteristic chemical shifts patterns in agreement with the literature (Ustyuzhanina et 
al., 2016). The proportions for each of the five constituent residues identified were 
determined from the 1H/13C HSQC spectrum. Integration of the key anomeric signals 
(between 4.4-4.7 ppm in 1H and 102-108 ppm in the 13C dimension) indicated a 
composition of: GlcA 40.4%, GlcA-3S 59.6% and GalNAc-4S 46.2%, GalNAc-6S 
2.5% and GalNAc-4,6-diS 28.3%.  
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      The GlcA β(1→3) GalNAc-4,6S disaccharide linkage was ascertained from cross 
peaks present at 4.472, 4.012 ppm of NOESY spectra collected with NOE interaction 
times of 120 and 240 μs. This linkage was further identified via cross peaks present in 
the HMBC spectrum at 4.472, 79.10 and 4.016, 106.68 ppm. Similarly, linkages present 
within the GlcA-3Si β(1→3) GalNAc-4Si, GlcA-3Si β(1→3) GalNAc-4Sii and GlcA-
3Si β(1→3) GalNAc-4,6S disaccharides were also observed via NOESY cross peaks at 
4.593, 3.997; 4.593, 3.986 and 4.593, 4.010 ppm respectively, however, these were 
partially overlapping. Two broad HMBC cross peaks, covering the region of the GlcA-
3Si linkage with GalNAc-4Si, -4Sii and -4,6S, were present at 4.593, 79.11-80.01 and 
3.968-4.018, 106.64 ppm suggesting a linkage between these residues, but they were not 
resolved into three pairs of cross peaks. The combination of NOESY and HMBC 
spectra also indicated GlcA-3Sii β (1→3) GalNAc-6Si disaccharide linkages via 
NOESY cross peaks at 4.550, 3.801 and 4.555, 3.698 ppm respectively. The NOESY 
cross peak for the GlcA-3Sii β (1→3) GalNAc-6Si disaccharide linkage was 
supplemented by HMBC cross peaks at 3.802,106.54 and 4.546,83.72 ppm. 
 
No signals corresponding to the disaccharides containing GlcA-2,3S were 
identified. This residue has been reported as part of another naturally-occurring CS from 
the same organism that was isolated under different conditions (Cavalcante et. al., 2018) 
and as the chemically over-sulfated CS, which was a contaminant of pharmaceutical 
heparin (Guerrini et al., 2008), but the characteristic 1H and 13C signals are not present 
in the present sample, thereby establishing the unique character of the present sCS 
polysaccharide. 
Chondroitin sulfate chains containing 3-O-sulfated GlcA are resistant to the 
action of chondroitinase AC-II, and chondroitinase ABC digestion of such 
oligosaccharides has been reported to result in the apparent disappearance of 3-O-
sulfated GlcA containing disaccharide residues (Sugahara et. al., 1996). Thus, it is likely 
that after chondroitinase ACII and ABC treatment of the present sCS polysaccharide 
that significant portions of the molecule remain undigested and are not be detected by 
absorbance at 232 nm on HPLC. In contrast, NMR analysis permitted all structural 
variants to be detected and, through correlation spectra, their assignments to be made 
(Table 1), even for previously rarely-reported substituents, such as the 3-O-sulfated 
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glucuronic acid the chemical shift patterns allowing sulfated positions to be inferred 
owing to the highly electronegative properties of the sulfate group. 
The natural occurrence of 3-O sulfated GlcA residues in CS chains is rare and it 
has been reported in only a few marine animal sources (Kitagawa, 1997; Mou et. al., 
2018; Sugahara at. al., 1996; Shetty et. al., 2009; Ustyuzhanina et al., 2016), suggesting 
that this pattern may require a specific enzyme. It has been shown that 3-O-sulfate 
groups at the non-reducing terminal GlcA residue of trombomodulin from human urine 
samples can be recognized by an HNK-1 (human natural killer-1) monoclonal antibody 
(Nadanaka et. al., 1998). Recently, HNK-1 sulfotransferase (HNK-1ST) that catalyzes 
3-O-sulfation of terminal GlcA in the HNK-1 carbohydrate antigen precursor has been 
also shown to be involved in the 3-O-sulfation of the linkage region of GlcA, leading to 
the generation of an unique HNK-1 epitope (Hashiguchi et. al., 2011; Nakagawa et. al., 
2011). 3-O-sulfated GlcA residues were described in other glycoproteins and glycolipid 
saccharide sequence in mammals (Ilyas, Dalakas, Brady, & Quarles, 1986). In all cases, 
it has been shown that this unique sulfation pattern requires the same 3-O-
sulfotransferase (Hashiguchi et. al., 2011; Nakagawa et. al., 2011), however, so far, no 
3-O-sulfotransferase responsible for the 3-O-Sulfation pattern in GlcA residues has 
been characterized for CS molecules obtained from marine sources. The CS 
biosynthesis is dictated by multiple enzymes, which can display organism-type specific 
patterns of expression, potentially leading to functional diversity of CSPGs among 
different animal species. The peculiar structural features of these compounds distinguish 
the biosynthetic process from the classical model of GAG biosynthesis, suggesting a 
relation between the pattern of GAG sulfation and animal evolution. 
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 Fig. 1. A 1H/13C HSQC spectrum of sCS with 1-dimensional 1H and 13C external 
projections obtained at 600 MHz in D2O at 343 K and referenced to 100 µM DSS. The 
letter G represents glucuronic acid and 3-O-sulfate groups are indicated by superscript 
3S while the letter A (aminosugar) represents N-acetyl β-D-galactosamine with 4-O-, 6-
O- and 4,6 di-O-sulfate groups indicated by superscripts 4S, 6S and 4,6S respectively. 
The superscripts i and ii represent the same residue type with different neighbouring 
residues, hence slightly different chemical shifts. Minor signals, including unsulfated 
GalNAc can also be detected (Supplementary Data Information). 
 
Table 1. 1H and 13C NMR HSQC assignments of sCS from Litopenaeus vannamei 
(Values in ppm at 70 °C). 
Residue  1 2 3 4       5 6 -COCH3 
GlcA 
1H 4.467 3.388 3.570 3.788 3.704 --- --- --- 
13C 106.681 75.367 76.846 83.749 79.557 --- --- --- 
GlcA-3Si 
1H 4.589 3.647 4.376 4.048 3.773 --- --- --- 
13C 106.637 75.301 84.947 80.998 80.025 --- --- --- 
GlcA-3Sii 
1H 4.551 3.625 4.372 4.052 3.829 --- --- --- 
13C 106.506 75.301 84.269 79.993 79.988 --- --- --- 
GalNAc-4Si 
1H 4.596 3.991 3.996 4.727 3.803 3.834 3.759 2.020 
13C 104.028 54.773 79.347 79.429 77.665 64.173 64.151 25.702 
GalNAc-4Sii 
1H 4.633 4.034 3.986 4.757 3.736 3.785 3.730 2.020 
13C 104.295 54.695 79.724 79.361 77.595 64.147 64.100 25.702 
GalNAc-6Si 1H 4.547 3.987 3.804 4.126 4.031 4.207 4.167 2.020 
AC
CE
PT
ED
 M
AN
US
CR
IPT
13C 104.109 54.018 83.825 70.572 78.692 70.391 70.400 25.702 
GalNAc-6Sii 
1H 4.577 3.996 3.692 4.136 4.076 4.269 4.208 2.020 
13C 104.503 54.001 77.909 70.232 75.566 70.905 70.837 25.702 
GalNAc-4,6S 
1H 4.671 4.007 4.006 4.778 3.962 4.268 4.241 2.020 
13C 103.223 54.734 79.114 79.480 75.405 70.120 70.078 25.702 
1Combined values for signals denoted i and ii in HSQC spectrum (Figure 1). 
 
2. Effect on coagulation time and mediators    
 
The anticoagulant activity of GAGs seems to be related, besides the degree of 
sulfation, to differences of GAG-ligand proteases or conformational changes during 
GAG-protein interactions (Nandini & Sugahara, 2006; Tiedemann et. al., 2005). The 
clotting time of sCS was investigated using an aPTT test, which assesses the intrinsic 
pathway of the coagulation cascade and by factor IIa and Xa directly and HCII-
mediated inhibition chromogenic assays. In the aPTT assay, sCS presented reduced 
anticoagulant activity (30 UI.mg-1) compared to commercial heparin (190 UI.mg-1), 
known for its high anticoagulant activity (Brito et. al., 2014) (Fig.2). A CS from the 
smooth hound shark (mustelus) composed mainly of monosulfated disaccharides in 
position 6 and 4 of the N-acetyl β-D-galactosamine (Krichen et. al., 2018), showed six 
times lower anticoagulant activity compared to sCS.  
Unlike heparin and its mimetics, which are capable of binding to both HCII and 
antithrombin and inhibiting proteases, the anticoagulant activity of CS usually arises 
through direct and HCII-mediated inhibition of thrombin (Casu, Guerrini, & Torri, 
2004; Karamanou et. al., 2017. In order to investigate the ability of sCS to promote FII 
inhibition chromogenic assays were carried out and the sCS achieved 80% anti-IIa 
activity at 1.0 µg/mL (Fig.3A). A similar effect (96% inhibition) was observed for a 
previously reported sCS (Cavalcante et. al., 2018), suggesting a particular anti-thrombin 
activity for marine CS that could be related, not only to coagulation mechanisms, but 
also to other biological effects displayed by marine CS. Furthermore,  although Xu and 
co-workers (Xu et. al., 2018) describe that the degree of fucosylation is an important 
feature for the anti-HCII-mediated thrombin activity of CS compounds, the sCS has 
achieved about 90% of anti-HCII-mediated thrombin activity at 100 µg/mL 
concentration (Fig.3B). Another protease that plays an important role in anticoagulant 
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activity, factor Xa, was evaluated. Figure 3C shows that the anti-Xa activity of sCS is 
notably lower than heparin, probably due to its inability to interact and stabilize AT 
(Fig.4). It was previously reported that there is a close relationship between AT thermal 
stabilization and anticoagulant activity of polysaccharides (Lima et al., 2013). These 
data could explain the moderate anticoagulant activity seen in the aPTT test. Similarly, 
no anti-Xa effect was described for other forms of sCS from L. vannamei (Cavalcante et 
al., 2018), suggesting a particular anticoagulant route for marine CS. Together, these 
findings emphasize the complex multifactorial relationships implicated in the inhibitory 
activities of sCS on the different mechanisms of blood coagulation. 
 
Fig. 2. Anticoagulant activity of sCS (●) and unfractionated heparin (○) measured by 
activated partial thromboplastin time (aPTT). Values are the mean of three independent 
experiments. 
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 Fig. 3. Anti-IIa activity (A), thrombin inhibition mediated by HCII (B) and anti-Xa 
activity (C) of sCS (●) and unfractionated heparin (○).The tests were conducted using 
chromogenic methods as mentioned in methods. Values are the mean of three 
independent experiments. 
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 Fig. 4 Effect of sCS on thermo-stabilization of antithrombin evaluated by differential 
scanning fluorimetry. Melting curve profile (first derivative) of 30 nM antithrombin in 
the presence or absence of different ligands. Antithrombin (black solid line); 
antithrombin+sCS (grey solid line); antithrombin+heparin (red solid line); 
antithrombin+pentasaccharide (blue dotted line).  
 
3. Hemorrhagic effect 
 
 Since the use of unfractionated heparin leads to disturbances in hemostasis, 
leading to hemorrhagic events, the residual hemorrhagic effect of sCS was investigated. 
Even at 5 times higher concentration (500 μg/mL), sCS exhibited no significant change 
in its effect on the residual bleeding when compared to its effect at lower concentration 
(100 μg/mL), showing almost no hemorrhagic activity (Fig.5). The strong binding of 
heparin to myosin ATPase receptors that were exposed during wounding, results in 
uncontrollable bleeding. The insignificant hemorrhagic activity presented by this sCS 
could be explained by the lack of binding or interaction to these receptors. Such a 
feature of sCS suggests that this compound has minimal bleeding effects. The structural 
differences of these GAGs influence their abilities to bind and control the functional 
interactions with biologically important proteins (Pomin & Mourão, 2014). Although 
various GAG structures have been characterized in several marine animals, including 
other L. vannamei GAGs (Brito et al., 2008, 2014; Cavalcante et. al. 2018; Chavante et 
AC
CE
PT
ED
 M
AN
US
CR
IPT
al., 2014), the biological roles of these unique structures have not been yet fully 
disclosed.   
 
 
Fig. 5. Hemorrhagic activity in a rat-tail scarification model. 100 μg/mL (●) and 500 
μg/mL of sCS (▲) or unfractionated heparin (○) was applied topically and the bleeding 
potency measured after 2 min following up to 40 min. The bars indicate the standard 
error of the measurements. 
 
 
4. Effect on LPS-induced peritonitis and cytokine production  
 
The structural peculiarity of CS enables it to display a wide range of biological 
activities, including anti-inflammatory effect (Lauder, 2009; Volpi, 2011). Previously, 
CS compounds obtained from several marine sources have been studied as potential 
anti-inflammatory agents (Cunha et. al., 2017; Krylov et. al., 2011; Mou et. al., 2018; 
Ustyuzhanina et. al., 2018).  
In this context, the in vivo anti-inflammatory effect of sCS was evaluated. The 
analysis of total leukocytes present in the peritoneal lavage showed a three-fold 
decrease in mice treated with sCS or heparin compared to untreated animals (PBS and 
PBS control groups)  (Fig. 6A). The sCS showed significantly reduced leukocyte 
recruitment, mainly PMN in approximately 60%, compared to the PBS group, while 
heparin achieved only 30% inhibition (Fig. 6B). Another GAG obtained from the same 
shrimp, also inhibited the leucocyte infiltration, as well as the activity of enzymes 
involved in this process (metalloproteinase 9 and pro-metalloproteinase 2) (Brito et. al., 
2008). Moreover, 45% of migratory inhibition were observed for a fucosylated CS 
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obtained from Cucumaria djakonovi sea cucumber, while a low fucosyl branched CS 
from another sea cucumber species presented 31% of leukocyte recruitment inhibition 
(Ustyuzhanina et. al, 2018). The interesting fact is that sea cucumber CS shares the 
presence of GalNAc-4,6 di-O-sulfate with this form of sCS. However, although the 
presence of fucosyl branches and a higher degree of sulfation are often reported as 
essential structural features for the more pronounced anti-inflammatory effects of CS 
compounds, the high PMN inhibition activity of this sCS suggests that there are other 
biochemical characteristics involved in this effect. 
There is supporting evidence that signaling through coagulation proteases makes 
an important contribution to the inflammatory response (Foley & Conway, 2016). As 
the main coagulation protease, thrombin is capable of inducing the expression of a 
variety of biological molecules mediated by PAR receptors modulating physiological 
and pathological process such as inflammation and cancer development, respectively 
(Coughlin, 2000; Zigler et. al. 2011). During the inflammation process, thrombin 
activates PAR-1, its signaling triggers the expression of pro-inflammatory cytokines 
(such as IL-1β, IL-6 and IL8), chemokines (such as MCP-1) and cell adhesion 
molecules, promoting the activation of leukocytes, leading to attachment, rolling and 
adhesion to endothelial surface, thus contributing to leukocyte recruitment (Foley & 
Conway, 2016; López et. al., 2014; Strande & Phillips, 2009). 
Furthermore, it is known that GAGs, including CS compounds are capable of 
binding cytokines, thereby mediating inflammatory responses (Lever, Mulloy, & Page, 
2012). Therefore, pro-inflammatory cytokine levels were quantified from peritoneal 
liquid. In animals treated with sCS, cytokine levels were sigficantly reduced, almost 
reaching the basal cytokines levels found for the PBS control group (healthy animals). 
IL-1β levels were about 64 % lower compared to PBS-treated animals, while for TNF-
α, the inhibition was approximately 82 % (Fig. 7). Inhibitory activity was also observed 
for IL-6 levels, in which the sCS reached about 64 % inhibition compared to the PBS 
group. The LPS injected into animals is adsorbed through interstitial fluid and serum 
and is degraded into the O-antigen, core protein and lipid-A, which is highly pro-
inflammatory. Lipid-A binds the CD14/TLR4/MD2 receptor of tissue macrophages and 
serum monocytes to trigger the activation of NF-κβ protein family, via a complex 
multiple step intracellular process, initiating the production of pro-inflammatory 
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cytokines, such as TNF-α, IL-1β, IL-6 and IL8 (Jaffer, Wade & Gourlay, 2010; 
Lawrence, 2009).  
 
The binding of cytokines to different GAGs is well-known and a minimal chain 
length seems to be required for this interaction. Mammalian CS has an IC50 value of 22 
mg/mL in cytokine interactions (Kuschert et. al., 1999). In joints, CS can reduce the 
concentrations of pro-inflammatory cytokines, such as TNF-α (Campo et. al., 2003) and 
IL-1β (Chou et. al., 2005). The link between coagulation and inflammatory process 
seems to have a refined molecular basis. Thrombin-treated monocytes exhibited 
increased transcriptional activation of NF-Κβ p50/p65, a triggering factor of 
inflammatory process (Zhang, 2010). These data could suggest a mechanism which by 
those compounds modulate their anti-inflammatory effect, either by direct cytokine-
binding or thrombin inhibitory signaling, such as activation of transcriptional factors 
involved in regulation of the immune response.  
 
Fig. 6. Polymorphonuclear cells (PMN) recruitment, in an inflammation model of 
peritonitis LPS-induced is inhibited by sCS. The mice were treated intraperitoneally 
with 100 µl of LPS 15 min before the intravenous injection of sCS, unfractionated 
heparin (300 µg Kg-1), or no treatment (PBS control group). After 4 hours, the 
peritoneal lavage fluid was evaluated for total cell number (A) and the percentage of 
PMNs (B). PMNs were identified by staining with hematoxylin and eosin. Statistical 
significance was determined by ANOVA (two-way) test and Bonferroni post-test (***p 
<0.001). The bars indicate the standard error of the measurements. Bar: 20 µM. 
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Fig. 7. IL-1β (A), IL-6 (B) and TNF-α (C) levels production stimulated by LPS in 
C57BL/6 mice after treatment with shrimp sCS, unfractionated heparin or no treatment 
(PBS). The results represent the average levels of cytokine (pg/ml) and standard 
deviations of the animals in each group when compared with each cytokine control. 
Statistical significance was determined by ANOVA (one-way) test and post-hoc Tukey 
test (** p < 0.01; *** p < 0.001). The bars indicate the standard error of the 
measurements. 
 
5. Inhibition of in vitro NO production and RAW 264.7 cell viability 
 
The rise in NO levels is stimulated through TNF-α production, activating a variety 
of biological effects such as platelet activation, bactericidal potential and immune 
system modulation (Bogdan, 2015). Once TNF-α production is inhibited, a decrease in 
NO levels was also expected. Thus, the NO production by macrophages was measured 
in the presence of different concentrations of the compounds. Both heparin and sCS 
reduced the NO production by macrophages at all tested dosages, however, at 100 
µg/mL, sCS achieved 55 % and heparin, 43 %, inhibition (Fig.8A). Importantly, this 
inhibition was not induced by cell toxicity, since the MTT viability test demonstrated 
that none of the GAG concentrations evaluated were able to induce cell death (Fig. 8B). 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Although it is clear that the GAGs bind to cytokines, it is still unclear which structural 
properties provide the high NO inhibiton potential of this polysacharide. Differences in 
chain length, disaccharide compositon or sulfation pattern might be implicated in these 
distinct biological activities. A fucosylated CS isolated from sea cucumber has 
exhibited similar NO reduction in a hepatic endoplasmatic reticulum stress-associated 
inflammation assay in obese mice (Hu et. al., 2015). These findings indicate that there 
are some notable characteristics among GAGs from marine sources, that remain to be 
unveiled. 
 
Fig. 8. Effects of unfractionated heparin and sCS on nitrite (NO) production in LPS-
stimulated RAW 264.7 macrophages. NO production was measured by the Griess 
reaction assay and expressed as a percentage of control (LPS alone) (A).  Effects of 
GAGs on cell viability. Cell viability was evaluated by MTT assay 24 h after GAG 
treatment in RAW264.7 macrophages (B). Values are the mean ± SD of the three 
independent experiments. Statistical significance was determined by ANOVA (two-
way) test and Bonferroni post-test (* p < 0.05; ** p < 0.01). The bars indicate the 
standard error of the measurements  
 
 
 
 
Conclusion  
 
Studies on the anti-inflammatory effects of non-fucosylated CS compounds are 
still scarce. The biological properties herein presented by the present sCS suggest its 
importance within the context of inflammation and hemostasis. Although oversulfated 
CS products derived from semi-synthetic routes were associated with the heparin 
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contamination crisis (Guerrini et. al., 2008), the peculiar structural composition of sCS 
(lacking 2, 3 di-sulfated GlcA residues or extensive per-sulfation of GalNAc residues) 
and the interesting biological effects reported here for this form of sCS suggest it as a 
biotechnological target for further exploration of the relationships between structure and 
function of GAGs. 
 
 
Addendum 
 
Each author contributed to the development of the manuscript and reviewed of each 
draft, and approved the final draft. L. C. G. F. Palhares conducted the in vivo and in 
vitro studies. A. S. Brito and S. F. Chavante contributed to the study design. J. London, 
I. Barsukov, M. A. Lima and H. B. Nader contributed to acquisition and analysis of 
structural data. E. A. Yates, G. P. V. Andrade and S. F. Chavante contributed to data 
interpretation. 
 
 
Acknowledgements 
 
This work was supported by grants from CNPq (Conselho Nacional de 
Desenvolvimento e Tecnológico – Project n. 4561602014-0), PPG.BIOQ (Programa de 
Pós-graduação em Bioquímica/UFRN), CAPES (Coordenação de Aperfeiçoamento de 
Pessoal de Nível Superior), FAPESP (Fundação de Amparo à Pesquisa do Estado de 
São Paulo 2017/14179-3 & 2015/03964-6), FINEP (Financiadora de Estudos e Projetos 
01/2013 - 736/13) and BBSRC (Biotechonology and Biological Sciences Research 
Council). Lais C.G.F. Palhares is recipient of a fellowship from CAPES and a PDSE 
(Programa de Doutorado Sanduíche no Exterior – contract 88881.187624/2018) 
exchange student.  
 
Disclosure of Conflict of Interests 
 
The authors state that they have no conflict of interest.   
AC
CE
PT
ED
 M
AN
US
CR
IPT
 References 
 
Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of 
microgram quantities of protein utilizing the principle of protein-dye binding. 
Analytical Biochemistry, 72, 248–254. 
Brito, A. S., Arimateia, D. S., Souza, L. R., Lima, M. A., Santos, V. O., 
Medeiros, V. P., et al. (2008). Anti-inflammatory properties of a heparin-like 
glycosaminoglycan with reduced anti-coagulant activity isolated from a marine 
shrimp. Bioorganic & Medicinal Chemistry, 16(21), 9588–9595. 
Brito, A. S., Cavalcante, R. S., Palhares, L. C., Hughes, A. J., Andrade, G. P., 
Yates, E. A., et al. (2014). A non-hemorrhagic hybrid heparin/heparan sulfate 
with anticoagulant potential. Carbohydrate Polymers, 99, 372–378. 
Bogdan, C. (2015). Nitric oxide synthase in innate and adaptive immunity: an 
update. Trends in Immunology, 36: 161-178. 
Campo G. M, Avenoso A, Campo S, Ferlazzo A. M, Altavilla D, Calatroni A. 
(2003). Efficacy of treatment with glycosaminoglycans on experimental 
collagen-induced arthritis in rats. Arthritis Research, 5, 122-131. 
 
Casu, B., Guerrini, M. & Torri, G. (2004). Structural and Conformational 
Aspects of the Anticoagulant and Antithrombotic Activity of Heparin and 
Dermatan Sulfate. Current Pharmaceutical Design, 10(9), 939-949. 
Cavalcante, R. S, Brito, A. S., Palhares, L. C., Andrade, M. L., Cavalheiro, R. P., 
Nader, H. B., Sassaki, G. L., Chavante, S. F. (2018). 2,3-Di-O-sulfo glucuronic 
acid: An unmodified and unusual residue in a highly sulfated chondroitin sulfate 
from Litopenaeus vannamei Carbohydrate Polymers, 183, 192–200. 
Chavante, S. F., Brito, A. S., Lima, M., Yates, E., Nader, H., Guerrini, M., et al. 
(2014). A heparin-like glycosaminoglycan from shrimp containing high levels of 
3-O-sulfated D-glucosamine groups in an unusual trisaccharide sequence. 
Carbohydrate Research, 390, 59–66. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
 Chou M. M, Vergnolle N, McDougall J. J, Wallace J. L, Marty S, Teskey V., et 
al. (2005). Effects of chondroitin and glucosamine sulfate in a dietary bar 
formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and 
cartilage damage in arthritis. Experimental Biology and Medicine, 230, 255-62. 
Coughlin, S. R. (2000). Thrombin signalling and protease-activated receptors. 
Nature, 407: 258–264. 
Cruz, W. O., & Dietrich, C. P. (1967). Antihemostatic effect of heparin 
counteracted by adenosine triphosphate. Proceedings of the Society for 
Experimental Biology and Medicine, 126(2), 420–426. 
Cunha, A. L., Aguiar, J. A. K., Silva, F. S. C., Michelacci, Y. M. (2017). Do 
chondroitin sulfates with different structures have different activities on 
chondrocytes and macrophages? International Journal of Biological 
Macromolecules, 103, 1019–1031. 
Dietrich, C. P., & Dietrich, S. M. C. (1976). Electrophoretic behaviour of acidic 
mucopolysaccharides in diamine buffers. Analytical Biochemistry, 70(2), 645–
647. 
Deepa, S. S., Yamada, S., Fukui, S. and Sugahara, K. (2007). Structural 
determination of novel sulfated octasaccharides isolated from chondroitin sulfate 
of shark cartilage and their application for characterizing monoclonal antibody 
epitopes. Glycobiology, 17(6), 631-45. 
Foley, J. H. & Conway, E. M. (2016). Cross Talk Pathways Between Coagulation 
and Inflammation. Circulation Research, 118:1392-1408. 
Guerrini, M., Beccati, D., Shriver, Z., Naggi, A. M., Bisio, A., Capila, I., et al., 
(2008) Oversulfated chrondroitin sulfate is a contaminant in heparin associated 
with adverse clinical events. Nature Biotechnology, 26, 669-675. 
Hashiguchi T., Mizumoto S., Nishimura Y., Tamura J., Yamada S., Sugahara K. 
(2011) Involvement of human natural killer-1 (HNK-1) sulfotransferase in the 
biosynthesis of the GlcUA(3-O-sulfate)-Gal-Gal-Xyl tetrasaccharide found in α-
AC
CE
PT
ED
 M
NU
SC
RI
PT
thrombomodulin from human urine. Journal of Biological Chemistry, 286, 
33003–33011. 
Hu, S., Jiang, W., Li, S., Song, W., Ji, L., Cai, L., et. al. (2015). Fucosylated 
chondroitin sulphate from sea cucumber reduces hepatic endoplasmic reticulum 
stress-associated inflammation in obesity mice. Journal of Functional Foods, 16: 
352-363. 
Ilyas, A. A., Dalakas, M. C., Brady, R. O., & Quarles, R. H. (1986). Sulfated 
glucuronyl glycolipids reacting with anti-myelin-associated glycoprotein 
monoclonal antibodies including IgM paraproteins in neuropathy: Species 
distribution and partial characterization of epitopes. Brain Research, 385(1), 1–
9. 
Iozzo R. V. and Schaefer, L. (2015). Proteoglycan form and function: A 
comprehensive nomenclature of proteoglycans. Matrix Biology, 42, 11-55.  
Jaffer, U., Wade, R.G., Gourlay, T. (2010). Cytokines in the systemic 
inflammatory response syndrome: a review. HSR Procedures in Intensively Care 
and Cardiovascular Anesthesia, 2: 161-175. 
 
Kale, V., Freysdottir, J., Paulsen, B. S., FriÐjónsson, Ó. H., HreggviÐsson, G. 
Ó., & Omarsdottir, S. (2013). Sulphated polysaccharide from the sea cucumber 
Cucumaria frondosa affect maturation of human dendritic cells and their 
activation of allogeneic CD4(+) T cells in vitro. Bioactive Carbohydrates & 
Dietary Fibre, 2, 108–117. 
Karamanou, K., Espinosa, D. C. R., Fortuna-Costa, A., Pavão, M. S. G. (2017). 
Biological function of unique sulfated glycosaminoglycans in primitive 
chordates. Glycobiology Journal, 34: 277–283. 
Kuschert, G. S., Coulin, F., Power, C. A., Proudfoot, A. E., Hubbard, R. E., 
Hoogewerf., et. al. (1999). Glycosaminoglycans interact selectively with 
chemokines and modulate receptor binding and cellular responses. Biochemistry, 
38(39): 12959-12968.  
AC
CE
PT
ED
MA
NU
SC
RI
PT
Krichen, F., Bougatef, H., Sayari, N., Capitani, F., Ben Amor I., Koubaa, I., et. 
al. (2018). Isolation, Purification and Structural Characterestics of Chondroitin 
Sulfate from Smooth hound Cartilage: In vitro Anticoagulant and 
Antiproliferative Properties. Carbohydrate Polymers 197, 451–459. 
Krylov, V. B., Grachev, A. A., Ustyuzhanina, N. E., Ushakova, N. A. 
Preobrazhenskaya, M. E., Kozlova, N. I., et. al. (2011). Preliminary structural 
characterization, anti-inflammatory and anticoagulant activities of chondroitin 
sulfates from marine fish cartilage. Russian Chemical Bulletin, 60, 746–753.  
Lauder, R.M. (2009). Chondroitin sulphate: A complex molecule with potential 
impact on a wide range of biological systems. Complementary Therapies in 
Medicine, 17, 56–62.  
Lawrence, T. (2009). The Nuclear Factor NF-kB Pathway in Inflammation. Cold 
Spring Harbor Perspectives in Biology, 1: a00165. 
Lever, R., Mulloy, B., & Page, C. P. (2012). Ed. Heparin-a century of progress 
(Vol. 207). Springer Science & Business Media. 
Lima, M. A., Hughes, A. J., Veraldi, N., Rudd, T. R., Hussain, R., Brito, A. S., et 
al. (2013). Antithrombin stabilisation by sulfated carbohydrates correlates with 
anticoagulant activity. Medicinal Chemistry Communication, 4(5), 870–873. 
Lopéz, M. L., Bruges, G., Crespo, G., Salazar, V., Deglesne, P. A., Schneider, H., 
et. al. (2014). Thrombin selectively induces transcription of genes in human 
monocytes involved in inflammation and wound healing. Thrombosis 
Haemostasis, 112. 992-998. 
Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: 
Application to proliferation and cytotoxicity assays. Journal of Immunology 
Methods, 65: 55-63. 
Mou, J., Li, Q., Qi, X. and Yang, j. (2018). Structural comparison, antioxidant 
and anti-inflammatory properties of fucosylated chondroitin sulfate of three 
edible sea cucumbers. Carbohydrate Polymers, 185, 41–47. 
AC
CE
PT
ED
 M
AN
US
CR
IPT
Nadanaka, S., Kitagawa H., Sugahara K.. (1998). Demonstration of the 
immature glycosaminoglycan tetrasaccharide sequence GlcA-β1-3Galβ1-
3Galβ1-4Xyl on recombinant soluble human α-thrombomodulin. A possible 
mechanism generating ‘part-time’ proteoglycan. Journal of Biological 
Chemistry, 273, 33728–33734. 
Nandini, C. D., Sugahara, K. (2006). Role of the Sulfation Pattern of 
Chondroitin Sulfate in its Biological Activities and in the Binding of Growth 
Factors. Advances in Pharmacology, 53, 253-279. 
Nakagawa N., Izumikawa T., Kitagawa H., Oka S. (2011).  Sulfation of 
glucuronic acid in the linkage tetrasaccharide by HNK-1 sulfotransferase is an 
inhibitory signal for the expression of a chondroitin sulfate chain on 
thrombomodulin. Biochemical and Biophysical. Research Communications, 415, 
109–113. 
Pavão, M. S. G., Vilela‐Silva, A. C., Mourão, P. A.S. (2006). Biosynthesis of 
Chondroitin Sulfate: From the Early, Precursor Discoveries to Nowadays, 
Genetics Approaches. Advances in Pharmacology, 53, 117-140. 
Pomin, V. H., & Mourão, P. A. (2014). Specific sulfation and glycosylation - A 
structural combination for the anticoagulation of marine carbohydrates. 
Frontiers in Cellular and Infection Microbiology, 4, 33. 
Pomin V.H. (2015). A dilemma in the glycosaminoglycan-based therapy: 
synthetic or naturally unique molecules? Medicinal Research Reviews, 35: 
1195–1219. 
Prabhakar, V., & Sasisekharan, R. (2006). The biosynthesis and catabolism of 
galactosaminoglycans. Advances in Pharmacology, 53, 69-115. 
  Shetty, A. K. Kobayashi, T., Mizumoto, S., Narumi, M., Kudo, Y., Yamada, S. 
et. al. (2009). Isolation and characterization of a novel chondroitin sulfate from 
squid liver integument rich in N-acetylgalactosamine(4,6-disulfate) and 
glucuronate(3-sulfate) residues. Carbohydrate Research, 344(12), 1526-1532. 
  Smith, A. A. (2017). INFOS: spectrum fitting software for NMR analysis. 
Journal Biomolecular NMR, 67(2), 77-94. 
AC
CE
PT
ED
MA
NU
SC
RI
PT
  Strande, J. L., and Phillips, S. A. (2009). Thrombin increases inflammatory 
cytokine and angiogenic growth factor secretion in human adipose cells in vitro. 
Journal of Inflammation, 6:4. 
Sugahara, K., Mikami, T., Uyama, T., Mizuguchi, S., Nomura, K., & Kitagawa, 
H. (2003). Recent advances in the structural biology of chondroitin sulfate and 
dermatan sulfate. Current Opinion in Structural Biology, 13(5), 612–620. 
Sugahara, K., Tanaka, Y., Yamada, S., Seno, N., Kitagawa, H., Haslam, S. M., et 
al. (1996). Novel sulfated oligosaccharides containing 3-O-sulfated glucuronic 
acid from king crab cartilage chondroitin sulfate K. Unexpected degradation by 
chondroitinase ABC. Journal of Biological Chemistry, 271(43), 26745–26754. 
Tomatsu, S., Shimada, T., Patel, P., Mason, R. W., Mikami, T., Kitagawa, H., et 
al. (2015). Chondroitin and keratan sulfate. In M. Gama, H. B. Nader, & H. A. O. 
Rocha (Eds.). Sulfated polysaccharides (pp. 17–71). New York: Nova Science 
Pub Inc. 
Ustyuzhanina, N.E., Bilan, M.I., Dmitrenok, A.S., Shashkov, A.S., Kusayakin, 
M.I., Stonik, V.A., Nifantiev, N.E., and Usov A.I., Structure and biological 
activity of a fucosylated chondroitin sulfate from the sea cucumber Cucumaria 
japonica. Glycobiology (2016) 26, 449-459. 
Ustyuzhanina, N. E., Bilan, M. I., Panina, E. G., Sanamyan, N. P., Dmitrenok, 
A. S., Tsvetkova, E. A. et. al. (2018). Structure and Anti-Inflammatory Activity 
of a New Unusual Fucosylated Chondroitin Sulfate from Cucumaria djakonovi. 
Marine Drugs, 16(10), 389. 
Vranken W. F., Boucher W., Stevens T. J., Fogh R. H., Pajon A., Llinas M., et. 
al. (2005). The CCPN Data Model from NMR Spectroscopy: Development of a 
Software Pipeline, Proteins 59, pp.687-696. 
Volpi, N. (2006). Chondroitin sulfate: Structure, role and pharmacological 
activity Volume 53, 1st Edition. London: UK Advances in Pharmacology. 
Volpi, N. (2011). Anti-inflammatory activity of chondroitin sulphate: new 
functions from an old natural macromolecule. Inflammopharmacology, 6, 299–
306.  
AC
CE
PT
ED
MA
NU
SC
RI
PT
Xu, L., Gao, N., Xiao, C. Lin, L. Purcell, S. W. Wu, M. et.al. (2018). Research 
paperModulating the degree of fucosylation of fucosylated chondroitinsulfate 
enhances heparin cofactor II-dependent thrombin inhibition. European Journal 
of Medicinal Chemistry, 154, 133-143. 
Zhang, T., Ma, Z., Wang, Y., Cheng, Z., et. al. (2010). Thrombin facilitates 
invasion of ovarian cancer along peritoneum by inducing monocyte 
differentiation toward tumor-associated macrophages-like cells. Cancer 
Immunology, Immunotherapy, 59(7): 1097-1108.  
Zhu, W., Ji, Y., Wang, Y., He, D., Yan, Y., Su., et. al. (2018). Structural 
characterization and in vitro antioxidant activities of chondroitin sulfate purified 
from Andrias davidianus cartilage. Carbohydrate Polymers, 196, 398–404. 
 
 Zigler, M., Kamiya, T., Brantley, E. C., Villares, G. J., Menashe Bar-Eli. 
(2011). PAR-1 and Thrombin: The Ties That Bind the Microenvironment to 
Melanoma Metastasis. Cancer Research, 71(21):6561-6. 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
